摘要垂体促肾上腺皮质激素(ACTH)瘤表达生长抑素受体(SSTR),主要亚型为SSTR2和SSTR5.SSTR2表达可因皮质醇作用而下调.临床上常用的生长抑素类似物奥曲肽和兰瑞肽主要作用于SSTR2,对库欣病无明显治疗作用.帕瑞肽是作用于SSTR多亚型的新型生长抑素类似物,基础和临床研究证实其可有效降低库欣病患者血、尿皮质醇,改善症状,为库欣病带来新的治疗前景.

abstractsSomatostatin receptors (SSTR) are expressed in adreno-corticotropic-hormone-secreting adenoma,which are mainly SSTR2 and SSTR5.SSTR2 can be downregulated by cortisol.Octreotide and lanreotide are the clinically approved somatostatin analogues which mainly bind to SSTR2 and show no effect on Cushing's disease.Pasireotide is a novel multi-receptor-targeted somatostatin analogue.It has been proved by basic experiments and clinical trials that pasireotide can efficiently decrease serum and urine cortisol level and improve symptoms,which holds promise for Cushing's disease.